OmniSeq and the University of Pittsburgh Medical Center (UPMC) are partnering ahead of a phase 2 clinical trial (NCT04326257) examining patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), according to a press release.
OmniSeq will employ its RNA sequencing gene expression profile assay for the selection of immunotherapy combinations for patients with this disease type enrolled in the trial’s population.
By employing a more personalized approach for the selection of novel immunotherapeutic combinations moving forward, response rates should improve and better predictive biomarkers of efficacy should develop further.
“We are excited for this collaboration and to be able to offer the gene expression profile technology to [patients with recurrent/metastatic HNSCC] who have failed prior immunotherapy,” principal investigator and co-leader of the Head & Neck…
